Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.600
0.00 (0.00%)
At close: Mar 6, 2026, 4:00 PM EST
1.630
+0.030 (1.87%)
After-hours: Mar 6, 2026, 5:17 PM EST
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$406,571
Profits / Employee
-$1,308,000
Market Cap
12.79M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| Curis | 34 |
| BioLineRx | 28 |
| BioCardia | 20 |
| Soligenix | 16 |
| NewcelX | 15 |
| Phio Pharmaceuticals | 5 |
TRAW News
- 16 days ago - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewsWire
- 7 weeks ago - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewsWire
- 4 months ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 4 months ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 5 months ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 7 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 7 months ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire